128 related articles for article (PubMed ID: 38364110)
1. The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease.
Brothers RO; Turrentine KB; Akbar M; Triplett S; Zhao H; Urner TM; Goldman-Yassen A; Jones RA; Knight-Scott J; Milla SS; Bai S; Tang A; Brown RC; Buckley EM
Blood; 2024 May; 143(21):2145-2151. PubMed ID: 38364110
[TBL] [Abstract][Full Text] [Related]
2. Quantifying the Cerebral Hemometabolic Response to Blood Transfusion in Pediatric Sickle Cell Disease With Diffuse Optical Spectroscopies.
Lee SY; Brothers RO; Turrentine KB; Quadri A; Sathialingam E; Cowdrick KR; Gillespie S; Bai S; Goldman-Yassen AE; Joiner CH; Brown RC; Buckley EM
Front Neurol; 2022; 13():869117. PubMed ID: 35847200
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
4. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
[TBL] [Abstract][Full Text] [Related]
5. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Han J; Saraf SL; Gordeuk VR
Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
[TBL] [Abstract][Full Text] [Related]
7. Voxelotor: A Novel Treatment for Sickle Cell Disease.
Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
[TBL] [Abstract][Full Text] [Related]
8. Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia.
Guilliams KP; Fields ME; Ragan DK; Eldeniz C; Binkley MM; Chen Y; Comiskey LS; Doctor A; Hulbert ML; Shimony JS; Vo KD; McKinstry RC; An H; Lee JM; Ford AL
Blood; 2018 Mar; 131(9):1012-1021. PubMed ID: 29255068
[TBL] [Abstract][Full Text] [Related]
9. Differential cerebral hemometabolic responses to blood transfusions in adults and children with sickle cell anemia.
Juttukonda MR; Lee CA; Patel NJ; Davis LT; Waddle SL; Gindville MC; Pruthi S; Kassim AA; DeBaun MR; Donahue MJ; Jordan LC
J Magn Reson Imaging; 2019 Feb; 49(2):466-477. PubMed ID: 30324698
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
[TBL] [Abstract][Full Text] [Related]
11. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
[TBL] [Abstract][Full Text] [Related]
12. Voxelotor for the Treatment of Sickle Cell Disease.
Fantasia HC; Morse BL
Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
[TBL] [Abstract][Full Text] [Related]
14. Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
Estepp JH
Am J Hematol; 2018 Mar; 93(3):326-329. PubMed ID: 29352729
[No Abstract] [Full Text] [Related]
15. Voxelotor for the treatment of sickle cell disease in pediatric patients.
Brown C; Tonda M; Abboud MR
Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
[TBL] [Abstract][Full Text] [Related]
16. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
[TBL] [Abstract][Full Text] [Related]
17. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
Green ML; Savic RM; Tonda M; Jorga K; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
[TBL] [Abstract][Full Text] [Related]
18. Preliminary evidence for cerebral capillary shunting in adults with sickle cell anemia.
Juttukonda MR; Donahue MJ; Davis LT; Gindville MC; Lee CA; Patel NJ; Kassim AA; Pruthi S; Hendrikse J; Jordan LC
J Cereb Blood Flow Metab; 2019 Jun; 39(6):1099-1110. PubMed ID: 29260615
[TBL] [Abstract][Full Text] [Related]
19. Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
Savic RM; Green ML; Jorga K; Zager M; Washington CB
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):687-697. PubMed ID: 35447014
[TBL] [Abstract][Full Text] [Related]
20. Patient perception of voxelotor treatment benefit in sickle cell disease.
Idowu M; Haque A; Williams EM; Sridhar A
J Investig Med; 2022 Jun; 70(5):1316-1319. PubMed ID: 35732337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
